Cargando...
Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies
Cemiplimab, a human monoclonal antibody targeting programmed cell death-1 (PD-1) receptor, demonstrated antitumor activity in patients with advanced malignancies and a safety profile comparable to other anti–PD-1 therapies. This population pharmacokinetics (PopPK) analysis of cemiplimab included 11,...
Guardado en:
| Publicado en: | J Pharmacokinet Pharmacodyn |
|---|---|
| Autores principales: | , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Springer US
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8225544/ https://ncbi.nlm.nih.gov/pubmed/33728546 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10928-021-09739-y |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|